More recently, inhibitors of the RET kinase, such as vandetanib [21] and cabozantinib [22], have shown evidence of significant progression- free survival benefit, and hence are FDA-approved for the treatment of patients with advanced MTC. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.